Tolbutamide

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Tolbutamide

Error creating thumbnail: File missing
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	US FDA: Tolbutamide
Pregnancy category	AU: C US: C (Risk not ruled out)
Routes of administration	Oral (tablet)
ATC code	A10BB03 (WHO) V04CA01 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Protein binding	96%
Metabolism	Hepatic (CYP2C19-mediated)
Elimination half-life	4.5 to 6.5 hours
Excretion	Renal
Identifiers
IUPAC name 3-butyl-1-(4-methylphenyl)sulfonyl-urea
CAS Number	64-77-7
PubChem CID	5505
DrugBank	APRD00267
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C12H18N2O3S
Molar mass	270.349 g/mol

WikiDoc Resources for Tolbutamide
Articles
Most recent articles on Tolbutamide Most cited articles on Tolbutamide Review articles on Tolbutamide Articles on Tolbutamide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Tolbutamide Images of Tolbutamide Photos of Tolbutamide Podcasts & MP3s on Tolbutamide Videos on Tolbutamide
Evidence Based Medicine
Cochrane Collaboration on Tolbutamide Bandolier on Tolbutamide TRIP on Tolbutamide
Clinical Trials
Ongoing Trials on Tolbutamide at Clinical Trials.gov Trial results on Tolbutamide Clinical Trials on Tolbutamide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Tolbutamide NICE Guidance on Tolbutamide NHS PRODIGY Guidance FDA on Tolbutamide CDC on Tolbutamide
Books
Books on Tolbutamide
News
Tolbutamide in the news Be alerted to news on Tolbutamide News trends on Tolbutamide
Commentary
Blogs on Tolbutamide
Definitions
Definitions of Tolbutamide
Patient Resources / Community
Patient resources on Tolbutamide Discussion groups on Tolbutamide Patient Handouts on Tolbutamide Directions to Hospitals Treating Tolbutamide Risk calculators and risk factors for Tolbutamide
Healthcare Provider Resources
Symptoms of Tolbutamide Causes & Risk Factors for Tolbutamide Diagnostic studies for Tolbutamide Treatment of Tolbutamide
Continuing Medical Education (CME)
CME Programs on Tolbutamide
International
Tolbutamide en Espanol Tolbutamide en Francais
Business
Tolbutamide in the Marketplace Patents on Tolbutamide
Experimental / Informatics
List of terms related to Tolbutamide

For patient information, click here

Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic drug sold under the brand name Orinase. This drug may be used in the management of type II diabetes if diet alone is not effective. Tolbutamide stimulates the secretion of insulin by the pancreas. Since the pancreas must synthesize insulin in order for this drug to work, it is not effective in the management of type I diabetes. It is not routinely used due to a higher incidence of adverse effects compared to newer second generation sulfonylureas, such as glyburide. Template:SIB Template:Oral hypoglycemics de:Tolbutamid

Template:WikiDoc Sources